Document Detail


Cooperative effects of hemin and anthracyclines in promoting terminal erythroid maturation in K562 human erythroleukemia cells.
MedLine Citation:
PMID:  1893971     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Simultaneous exposure to 30 microM hemin and 3 x 10(-8) M aclacinomycin (ACL) or mussetamycin for 6 days led to terminal differentiation of K562 cells. The number of hemoglobinized cells and the total hemoglobin content of cells treated with both ACL and hemin exceeded the sum of the corresponding values induced in response to each of these two agents when used alone. Although neither ACL nor hemin alone induced substantial morphological maturation, 40%-45% of cells treated with both agents developed the morphological characteristics of orthochromatophilic normoblasts, a level of maturation not previously reported for this highly malignant cell line. Subcloning of K562 cells that had been treated with both ACL and hemin in inducer-free plasma clots revealed a 50% decrease in the clonogenic potential of these cells, even though the cells in the original cultures were still growing at only a moderately decreased rate. Despite the apparent terminal maturation of K562 cells induced with both ACL and hemin, with an advanced level of morphologic maturation and hemoglobin synthesis accompanied by a loss of proliferative capacity, these cells remained incapable of producing beta-globin chains and hence hemoglobin A.
Authors:
A S Tsiftsoglou; W Wong; A I Tsamadou; S H Robinson
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Experimental hematology     Volume:  19     ISSN:  0301-472X     ISO Abbreviation:  Exp. Hematol.     Publication Date:  1991 Oct 
Date Detail:
Created Date:  1991-10-24     Completed Date:  1991-10-24     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  0402313     Medline TA:  Exp Hematol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  928-33     Citation Subset:  IM    
Affiliation:
Charles A. Dana Research Institute, Boston, Massachusetts.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aclarubicin / analogs & derivatives*,  pharmacology
Benzidines / analysis
Cell Differentiation / drug effects
Drug Synergism
Erythroid Precursor Cells / drug effects*
Hemin / pharmacology*
Hemoglobins / analysis
Humans
Leukemia, Erythroblastic, Acute / pathology*
Tumor Cells, Cultured / chemistry,  drug effects,  pathology
Grant Support
ID/Acronym/Agency:
AM 17148/AM/NIADDK NIH HHS; CA 37727/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Benzidines; 0/Hemoglobins; 0/aclacinomycins; 16009-13-5/Hemin; 57576-44-0/Aclarubicin; 92-87-5/benzidine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Platelet factor 4 gene expression in a human megakaryocytic leukemia cell line (CMK) and its differe...
Next Document:  Differentiation of chimeric bone marrow in vivo reveals genotype-restricted contributions to hematop...